Hepatotoxicity induced by Rifampicin and Isoniazid – A suggested method for screening of hepatoprotective agents

Tuberculosis is one of the leading causes of death worldwide. Rifampicin and isoniazid are drugs of choice used to treat the disease since they are highly active against Mycobacterium species. However, both drugs exert significantly adverse effects on liver function. Thus, in combination with anti-tuberculosis therapy, adjunctive hepatoprotection by appropriate medications should be considered in clinical practice. What kind of medication may be indicated is still an open question that requires both experimental and clinical investigations. Here, we suggested a method for screening of hepatoprotective agents against rifampicin and isoniazid-induced liver injury.

(Nguồn tin: )